Novasep expands again at biologics site in Belgium

woman with back to camera working in a laboratory
Novasep is adding a fiill finish facility at its Belgium site to handle monoclonal antibodies, as well as other low-volume products. (Michal Jarmoluk)

French CDMO Novasep says with so many of its customers developing orphan and targeted biopharmaceutical drugs, it needs to expand its fill-finish capacity. That has led it to start on a facility at its site in Seneffe, Belgium to handle low-volume biologics like viral vectors and mAbs. 

The Lyon, France-based Novasep recently said it will invest €10 million ($11.9 million) to construct the facility. It will be able to fill 20,000 to 30,000 vials per week. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“The trend towards targeted therapies has created a growing need for specialized capacities,” Jean Bléhaut, Novasep’s president of manufacturing, said in a statement. “In response, Novasep has launched a series of major projects to boost its biomanufacturing services for selected types of drug substances and fill and finish activities.”

The fill-finish facility is the third expansion project Novasep has announced in recent months as it moves toward doubling its manufacturing capacity by 2022. It is also building a €27 million commercial scale viral vector production facility at Seneffe that is slated to be qualified by the first quarter of 2019.

A €17 million clinical scale mAb production facility in Pompey, France, is slated to commissioned in the second half of 2019.

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.